Learn About Poliomyelitis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Poliomyelitis Local Doctors?
FB
Filimona Bisrat
Elite
Highly rated in
3
conditions

CORE Group Polio Project/Ethiopia

Addis Ababa, AA, ET 

Filimona Bisrat is in Addis Ababa, Ethiopia. Bisrat is rated as an Elite expert by MediFind in the treatment of Poliomyelitis. They are also highly rated in 3 other conditions, according to our data. Their top areas of expertise are Poliomyelitis, Myelitis, Encephalitis, and Measles.

View Profile
RS
Roland W. Sutter
Roland W. Sutter
Elite
Highly rated in
4
conditions

Research

Policy And Containment, World Health Organization 
Geneve, GE, CH 

Roland Sutter is in Geneve, Switzerland. Sutter is rated as an Elite expert by MediFind in the treatment of Poliomyelitis. He is also highly rated in 4 other conditions, according to our data. His top areas of expertise are Poliomyelitis, Myelitis, Encephalitis, and Primary Immunodeficiency.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
NG
Nicholas C. Grassly
Elite
Highly rated in
5
conditions

NIHR Imperial Biomedical Research Centre

GB 

Nicholas Grassly is in United Kingdom. Grassly is rated as an Elite expert by MediFind in the treatment of Poliomyelitis. He is also highly rated in 5 other conditions, according to our data. His top areas of expertise are Poliomyelitis, Myelitis, Encephalitis, and Trachoma.

View Profile
View All Doctors
What are the Latest Advances for Poliomyelitis?
Clinical-etiological and MRI parallels of encephalitis in children.
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 18, 2022
View publication
Summary: Clinical-etiological and MRI parallels of encephalitis in children.
Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 11, 2022
View publication
Summary: Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave.
Tired of the same old research?
Check Latest Advances
Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey.
Journal: BMC infectious diseases
Published: January 06, 2022
View publication
Summary: Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey.
View All Latest Advances
What are the latest Poliomyelitis Clinical Trials?
Physical Activity in People With Sequelae of Poliomyelitis : a Cross-sectional Study
Status: Recruiting
Start Date: April 1, 2022
Intervention Type: Other
View Trial
Summary: People with disabilities are less physically active than the general population. At present, the physical activity level of people with poliomyelitis sequelae and their barriers to physical activity are unknown.~The aim of this study is to describe the physical activity level of people with poliomyelitis sequelae and their barriers to physical activity.
Match to trials
Find the right clinical trials for you in under a minute
Get started
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents
Who is this study for: Patients with Meningococcal Infection
Status: Active, not recruiting
Start Date: March 16, 2021
Intervention Type: Biological
Phase: Phase 3
View Trial
Summary: Primary Objective:~To demonstrate the non-inferiority of the seroprotection rate (serum bactericidal assay using human complement [hSBA] titer ≥ 1:8) to meningococcal serogroups A, C, W, and Y following the administration of a single dose of MenACYW conjugate vaccine (Group 1) compared to a single dose of Nimenrix® (Group 2)~Secondary Objective:~To describe:~the antibody response of meningococcal ...
View All Clinical Trials